

Kenneth W. Dawes, MD

Dawes Fretzin Clinical Research Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5030
Fax (317) 516-5031
E-mail: kdawes@ecommunity.com

Dawes Fretzin Dermatology Group, LLC

7910 North Shadeland Avenue
Indianapolis, Indiana 46250
Phone (317) 516-5000
Fax (317) 516-5031

Education

Indiana University Medical Center (Indianapolis, IN)
Dermatology Residency, 1992-95

St. Vincent Hospitals and Health Services (Indianapolis, IN)
Internal Medicine Residency, 1989-92

Indiana University School of Medicine (Indianapolis, IN)
Medical Doctorate, 1989

Indiana University (Bloomington, IN)
Bachelor of Arts in Biology, 1985

Northfield High School (Wabash County, IN)
Diploma, 1981

Professional Experience

Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Investigator, 2004-Present

Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Dermatologist, 1995-Present
Investigator, 2002-Present

Walker Clinical Evaluations (Indianapolis, IN)
Sub investigator, 1994-1995

Vencor Hospital (Indianapolis, IN)
House Physician, 1993-1995

Robert J. Steele, Internal Medicine (Kokomo, IN)
Cross-coverage for multiple physicians, 1992-1995

Johnson County Internal Medicine (Franklin, IN)
Hospital-based coverage, 1992-1995

Kenneth W. Dawes
6/16/26

Kenneth W. Dawes, MD

Professional Experience – continued

Physician's Weight Loss Center (Indianapolis, IN)
House Physician, 1992

Northside Cardiology P.C. (Indianapolis, IN)
Hospital-based coverage, 1990-1992

St. Vincent Hospitals and Health Services (Carmel, IN)
House Physician, 1990-1992

St. Vincent Hospitals and Health Services (Indianapolis, IN)
House Extern, 1989-1990

Honors and Awards

1995 Young Investigator's Award, Second place, Journal of Dermatologic surgery and Oncology
1994-95 Chief Resident, Dermatology
1985 Cum Laude at Indiana University, Bloomington, Indiana
1981 Phi Beta Kappa, Indiana University, Bloomington, Indiana
1981 Valedictorian, Northfield High School

License/Certifications

Board Certified in Dermatology, October 22, 1995
Board Certified in Internal Medicine, September 16, 1992, Certificate #146725
National Board of Medical Examiners, July 1, 1990, Certificate #374396
Indiana State License #01038446
ACLS Certified
CITI GCP Certification

Professional Societies

American Academy of Dermatology
Indiana State Medical Association
Indiana Academy of Dermatology, Secretary/Treasurer, 2010-2012
Indiana Academy of Dermatology, President, 2012 - 2014

Articles and Publications

Fretzin S., Dawes K. *J Am Acad Dermatol* 2005; 52:P182. Abstract P2745.
Dermatofibrosarcoma Protuberans Treated with Mohs Micrographic Surgery: Cure Rates and Surgical Margins, *Journal of Dermatologic Surgery and Oncology*, June 1996.

Kenneth W. Dawes, MD

Clinical Studies conducted at Dawes Fretzin Clinical Research Group, LLC

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Aczone	225678-007	Acne	PI	3	01-Mar-16
Allergan	225678-007	Acne	PI	3	21-Jan-15
Bausch Health	V01-121A-501	Acne	PI	1b	01-Oct-19
Dr. Reddy's	DFD-03-CD-006	Acne	PI	2	31-Jul-18
Elorac	EL-1006-01-01	Acne	PI	2	06-Jun-17
Foamix	FX2017-22	Acne	PI	2	28-Sep-18
Galderma	RD-06-SPR-18088	Acne	PI	3	22-Jan-08
Johnson & Johnson	732-ACN-2035	Acne	PI	4	01-Jun-07
Ranbaxy	ABS1517LT	Acne	PI	4	24-Apr-18
Sanoil	VBE00001	Acne	PI	1/2	24-Feb-26
Stiefel	W0260-301	Acne	PI	3	18-Jan-11
Taro	CLBG1210	Acne	PI	3	04-Feb-14
Valeant	V01-123A-501	Acne	PI	1b	14-Mar-17
Warner Chilcott	PR-10411	Acne	PI	2	09-Jan-13
Bausch Health	V01-121A-302	Acne	Sub-I	3	01-Mar-21
Cipher Pharma	ISOCT.08.01	Acne	Sub-I	3	18-Oct-11
Cipher Pharma	RAN.13.01	Acne	Sub-I	3	13-Mar-14
Dow Pharma Sciences	DPSI-IDP-107-P2-02	Acne	Sub-I	2	14-Jun-11
Foamix	FX2014-05	Acne	Sub-I	3	27-Apr-17
Novum	70608502	Acne	Sub-I	2	03-Sep-08
Stiefel	W0261-301	Acne	Sub-I	3	22-Oct-09
UPENN	Acne	Acne	Sub-I	4	16-Apr-25
Valeant	V01-121A-302	Acne	Sub-I	3	09-May-17
3M Pharmaceuticals	1502-IMIQ	Actinic Keratosis	PI	3b	04-Aug-05
Actavis	094-3153-301	Actinic Keratosis	PI	4	11-Jun-14
Actavis	094-8151-301	Actinic Keratosis	PI	4	17-Dec-15
Actavis	094-8152-301	Actinic Keratosis	PI	4	22-May-17
LEO	LP0084-1148	Actinic Keratosis	PI	2	15-Sep-15
LEO	LP0105-1012	Actinic Keratosis	PI	1/2	13-Aug-14
LEO	LP0105-1032	Actinic Keratosis	PI	3	13-Oct-17
Peplin	PEP005-016	Actinic Keratosis	PI	3b	07-Jan-10
Peplin	PEP005-020	Actinic Keratosis	PI	3b	26-Mar-10
Peplin	PEP005-028	Actinic Keratosis	PI	3b	21-Jan-10
Peplin	PEP005-030	Actinic Keratosis	PI	3b	11-Jan-11
Peplin	PEP005-032	Actinic Keratosis	PI	3b	11-Jan-11
Perrigo	PRG-NY-14-019	Actinic Keratosis	PI	3	14-Dec-15
3M Pharmaceuticals	1502-IMIQ	Actinic Keratosis	Sub-I	3b	04-Aug-05
3M Pharmaceuticals	1502-IMIQ-13	Actinic Keratosis	Sub-I	3b	06-Jun-07
Athenex	KX01-AK-004	Actinic Keratosis	Sub-I	3	21-Nov-19
Merck	A-11107	Allergen Immunotherapy	PI	OBS	09-Apr-13
Adelphi	AG9909	Alopecia Areata	PI	OBS	15-Apr-26

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
AnaptysBio	ANB030-201	Alopecia Areata	PI	2	22-Mar-23
Arena	APD334-205	Alopecia Areata	PI	2	30-Aug-23
Aslan	ASLAN003-004	Alopecia Areata	PI	2a	12-Aug-24
Concert	CP543.3001	Alopecia Areata	PI	3	13-Jul-23
Concert	CP543.5001	Alopecia Areata	PI	3	28-Apr-26
DrenBio	DR-01-AIM-001	Alopecia Areata	PI	1b	ONGOING
DRG Abacus	7785	Alopecia Areata	PI	OBS	01-Sep-19
Evidera	EVA-20417-00	Alopecia Areata	PI	OBS	11-Mar-20
HCW Biologics	HCWALO101	Alopecia Areata	PI	1b	ONGOING
Horizon	HZNP-DAX-201	Alopecia Areata	PI	2a	28-Mar-23
Inmagene	IMG-007-002	Alopecia Areata	PI	1b/2a	28-Jun-24
Lilly	I4V-MC-JAIO	Alopecia Areata	PI	3	ONGOING
Sanofi	DRI18180	Alopecia Areata	PI	2	10-Feb-25
Sun Pharma	CP543.3101	Alopecia Areata	PI	3	ONGOING
Abbvie	M24-725	Alopecia Areata	Sub-I	3	ONGOING
CorEvitas	AA-565	Alopecia Areata	Sub-I	OBS	ONGOING
Lilly	I4V-MC-JAIR	Alopecia Areata	Sub-I	3	13-Mar-25
Pfizer	B7931005	Alopecia Areata	Sub-I	2a	12-Mar-19
Pfizer	B7981015	Alopecia Areata	Sub-I	2b/3	03-Aug-21
Pfizer	B7981027	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981028	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981031	Alopecia Areata	Sub-I	1	17-Oct-23
Pfizer	B7981032	Alopecia Areata	Sub-I	3	01-Aug-24
Pfizer	B7981094	Alopecia Areata	Sub-I	3	ONGOING
Pfizer	B7981110	Alopecia Areata	Sub-I	3	ONGOING
Reistone	RSJ10521	Alopecia Areata	Sub-I	2	26-Aug-21
Pelage	PP405-2001	Androgenetic Alopecia	PI	2a	24-Nov-25
Pelage	PP405-2002	Androgenetic Alopecia	PI	2/3	ONGOING
Veradermics	250-13951-302	Androgenetic Alopecia	PI	3	ONGOING
Veradermics	250-13951-306	Androgenetic Alopecia	PI	3	ONGOING
GSK	SAS115358	Asthma	PI	4	30-Oct-13
GSK	SAS115359	Asthma	PI	4	01-May-14
Aclaris	ATI-1777-AD-201	Atopic Dermatitis	PI	2a	23-Jun-21
Aclaris	ATI-1777-AD-202	Atopic Dermatitis	PI	2b	06-Feb-24
Acrotech	MEDI-MM36-301	Atopic Dermatitis	PI	3	20-Nov-23
Acrotech	MEDI-MM36-302	Atopic Dermatitis	PI	3	16-Jul-24
Alumis	ESK-001-006	Atopic Dermatitis	PI	2	08-Sep-23
Alumis	ESK-001-007	Atopic Dermatitis	PI	2	13-Feb-24
Arcutis	ARQ-151-212	Atopic Dermatitis	PI	2	10-Dec-19
Arcutis	ARQ-151-313	Atopic Dermatitis	PI	3	11-Jul-23
Asana	ASN002AD-201	Atopic Dermatitis	PI	2b	25-Sep-19
Asana	ASN002AD-201-EXT	Atopic Dermatitis	PI	2	10-Mar-20
Astellas	FHI-03-0-161/FG-506-06-37	Atopic Dermatitis	PI	2	01-Oct-12
Attovia	ATTO-3712-101	Atopic Dermatitis	PI	1	ONGOING

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
BMS	IM011-005	Atopic Dermatitis	PI	2	01-Aug-22
BMS	IM018-005	Atopic Dermatitis	PI	2	20-Sep-22
BMX	BMX-DERM-01	Atopic Dermatitis	PI	1/2	24-Aug-21
Gelgene	CO-93538-AD-001	Atopic Dermatitis	PI	2	07-Dec-22
Ceragenix	CPI-2006-002	Atopic Dermatitis	PI	2	23-Apr-07
Dermavant	RVT-501-2007	Atopic Dermatitis	PI	1b	03-Aug-18
DermTech	20-03	Atopic Dermatitis	PI	4	24-Oct-23
Enveda	ENV-294-202	Atopic Dermatitis	PI	2b	ONGOING
Evidera	EVA-25835	Atopic Dermatitis	PI	OBS	16-Dec-23
Evommune	EVO101-AD001	Atopic Dermatitis	PI	2a	29-Aug-23
Galapagos	MOR106-CL-204	Atopic Dermatitis	PI	2	28-Oct-19
GSK	201551	Atopic Dermatitis	PI	3	07-Jul-05
GSK	215253	Atopic Dermatitis	PI	1b	13-Jun-23
Incyte	INCB18424-206	Atopic Dermatitis	PI	2	18-May-18
Janssen	77474462ADM2001	Atopic Dermatitis	PI	3	16-May-22
Janssen	77474462ADM2003	Atopic Dermatitis	PI	2a	06-Apr-22
Kiniksa	KPL-716-C001	Atopic Dermatitis	PI	1b	20-Sep-19
LEO	LP0145-2240	Atopic Dermatitis	PI	2b	25-Jun-25
LEO	LP0162-1326	Atopic Dermatitis	PI	3	15-Oct-19
LEO	LP0162-1337	Atopic Dermatitis	PI	3	27-Jan-23
LEO	LP0156-1294	Atopic Dermatitis	PI	OBS	24-Oct-17
Lilly	J2T-MC-B002	Atopic Dermatitis	PI	4	ONGOING
Lilly	J2T-MC-KGBP	Atopic Dermatitis	PI	3b	02-Apr-25
Organon	OG0505-3104	Atopic Dermatitis	PI	3	ONGOING
Ralexar	ALX-101-ATOP-204	Atopic Dermatitis	PI	2	27-Jan-20
Rapt	RPT193-01	Atopic Dermatitis	PI	1	26-Jul-21
Rapt	RPT193-02	Atopic Dermatitis	PI	2	07-Jun-24
TARGET-DERM	TARGET-DERM	Atopic Dermatitis	PI	4	06-Apr-26
Taro	TACR-0707	Atopic Dermatitis	PI	2	12-May-09
Triveni Bio	TRIV-509-101	Atopic Dermatitis	PI	2a	ONGOING
Triveni Bio	TRIV-573-101	Atopic Dermatitis	PI	2	ONGOING
Xbiotech	2019-PT046	Atopic Dermatitis	PI	2	21-Feb-21
Abbvie	M16-045	Atopic Dermatitis	Sub-I	3	04-Feb-26
Abbvie	M16-046	Atopic Dermatitis	Sub-I	3b	01-Feb-21
Abbvie	M16-047	Atopic Dermatitis	Sub-I	3	ONGOING
Abbvie	M16-049	Atopic Dermatitis	Sub-I	2b	29-Oct-24
Abbvie	M17-380	Atopic Dermatitis	Sub-I	3	ONGOING
Abbvie	M19-850	Atopic Dermatitis	Sub-I	3b	21-Apr-22
Abbvie	M23-696	Atopic Dermatitis	Sub-I	3b/4	29-Oct-24
Abbvie	M24-601	Atopic Dermatitis	Sub-I	3b/4	12-Jun-25
Aclaris	ATI-045-AD-201	Atopic Dermatitis	Sub-I	2b	ONGOING
Amgen	20210144	Atopic Dermatitis	Sub-I	3	29-Apr-25
Amgen	20210145	Atopic Dermatitis	Sub-I	3	26-Feb-26
Amgen	20210146	Atopic Dermatitis	Sub-I	3	ONGOING

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Anacor	AN2728-AD-203	Atopic Dermatitis	Sub-I	2a	21-Jan-13
Anacor	AN2728-AD-301-302-POST01	Atopic Dermatitis	Sub-I	OBS	ONGOING
Anacor	AN2728-AD-302	Atopic Dermatitis	Sub-I	3	11-Aug-15
Anacor	AN2728-AD-303	Atopic Dermatitis	Sub-I	3	11-Nov-15
Apogee	APG777-301	Atopic Dermatitis	Sub-I	3	ONGOING
Apollo	AP43CP03	Atopic Dermatitis	Sub-I	2	04-Nov-25
Apollo	AP43CP04	Atopic Dermatitis	Sub-I	2b	ONGOING
Aslan	ASLAN004-003	Atopic Dermatitis	Sub-I	2b	04-Jan-24
Biosion	BSI-045B-002	Atopic Dermatitis	Sub-I	2a	18-Jul-24
Cara	CR845-310501	Atopic Dermatitis	Sub-I	3	07-Mar-24
CastleBio Science	CBI_2021_ISD_DevVal_001	Atopic Dermatitis	Sub-I	4	02-Dec-25
Chugai	CIM003JG	Atopic Dermatitis	Sub-I	2	20-Oct-16
Connect	CBP-201-WW004	Atopic Dermatitis	Sub-I	3	30-Dec-22
CorEvitas	AD-550	Atopic Dermatitis	Sub-I	4	ONGOING
Corrona	Corrona-AD-550	Atopic Dermatitis	Sub-I	4	ONGOING
Dermavant	RVT-502-2001	Atopic Dermatitis	Sub-I	2	01-Aug-18
Dermira	DRM06-AD01	Atopic Dermatitis	Sub-I	2b	30-Jul-19
Dermira	DRM06-AD07	Atopic Dermatitis	Sub-I	3	09-Apr-25
Dermira	DRM06-AD17	Atopic Dermatitis	Sub-I	3	24-Aug-22
Galderma	RD.06.SPR.118126	Atopic Dermatitis	Sub-I	2	11-Jun-25
Galderma	RD.06.SPR.118161	Atopic Dermatitis	Sub-I	3	13-Feb-23
Galderma	RD.06.SPR.118163	Atopic Dermatitis	Sub-I	3	20-Jan-26
Galderma	RD.06.SPR.118380	Atopic Dermatitis	Sub-I	2	21-Dec-23
Galderma	SPR207806	Atopic Dermatitis	Sub-I	OBS	ONGOING
Genentech	ACD3331g	Atopic Dermatitis	Sub-I	2	06-Oct-05
GSK	203121	Atopic Dermatitis	Sub-I	2	29-Mar-17
GSK	205050	Atopic Dermatitis	Sub-I	2a	11-Jan-18
Incyte	INCB18424-303	Atopic Dermatitis	Sub-I	3	28-Jan-21
Incyte	INCB18424-305	Atopic Dermatitis	Sub-I	3	26-Jun-24
Incyte	INCB18424-902	Atopic Dermatitis	Sub-I	4	05-Feb-25
Janssen	95475939ADM2001	Atopic Dermatitis	Sub-I	2b	12-May-26
Janssen	95597528ADM2001	Atopic Dermatitis	Sub-I	2b	ONGOING
Kymab	KY1005-CT05	Atopic Dermatitis	Sub-I	2b	02-May-24
Kyowa Hakko Kirin	4083-006	Atopic Dermatitis	Sub-I	2	15-Sep-20
LEO	LP0133-1181	Atopic Dermatitis	Sub-I	1	25-Jun-20
Lilly	F1P-MC-KFAD	Atopic Dermatitis	Sub-I	1	21-Jun-22
Lilly	I4V-MC-JAHL	Atopic Dermatitis	Sub-I	3	06-Dec-18
Lilly	I4V-MC-JAHN	Atopic Dermatitis	Sub-I	3	21-Sep-20
Lilly	I4V-MC-JAIW	Atopic Dermatitis	Sub-I	3	03-Aug-20
Lilly	I4V-MC-JAIX	Atopic Dermatitis	Sub-I	3	03-Aug-20
Lilly	J2T-MC-KGBO	Atopic Dermatitis	Sub-I	3b	01-Apr-25
Lilly	J2T-MC-KGCE	Atopic Dermatitis	Sub-I	4	ONGOING
MedImmune	D5240C00001	Atopic Dermatitis	Sub-I	2a	22-Sep-16
Novan	NI-AD101	Atopic Dermatitis	Sub-I	1b	25-Jun-18

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Novartis	CBPR277X2101	Atopic Dermatitis	Sub-I	1	13-Feb-13
OM1	DataDerm	Atopic Dermatitis	Sub-I	OBS	19-Aug-23
Pfizer	B7451006	Atopic Dermatitis	Sub-I	2b	26-Apr-17
Pfizer	B7451012	Atopic Dermatitis	Sub-I	3	23-May-19
Pfizer	B7451013	Atopic Dermatitis	Sub-I	3	27-Jun-19
Pfizer	B7451014	Atopic Dermatitis	Sub-I	3	19-Nov-20
Pfizer	B7451015	Atopic Dermatitis	Sub-I	3	25-Mar-25
Pfizer	B7451023	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	B7451031	Atopic Dermatitis	Sub-I	3	ONGOING
Pfizer	B7451036	Atopic Dermatitis	Sub-I	3	21-May-20
Pfizer	B7451050	Atopic Dermatitis	Sub-I	3b	12-Aug-21
Pfizer	C0341001	Atopic Dermatitis	Sub-I	1	09-Oct-18
Pfizer	C3941002	Atopic Dermatitis	Sub-I	2a	15-Nov-21
Pfizer	C3941005	Atopic Dermatitis	Sub-I	2b	01-Aug-23
Pfizer	C4531002	Atopic Dermatitis	Sub-I	2	ONGOING
Pfizer	C4531005	Atopic Dermatitis	Sub-I	3	ONGOING
Qurient	Q301-AD-P2-US002	Atopic Dermatitis	Sub-I	2	07-Jan-20
Regeneron	R668-AD-1225	Atopic Dermatitis	Sub-I	3	27-Sep-17
Regeneron	R668-AD-1314	Atopic Dermatitis	Sub-I	2	10-Dec-15
Regeneron	R668-AD-1334	Atopic Dermatitis	Sub-I	3	31-May-16
Regeneron	R668-AD-1415	Atopic Dermatitis	Sub-I	3	08-Feb-17
Regeneron	R668-AD-1434	Atopic Dermatitis	Sub-I	3	09-Dec-20
Regeneron	R668-AD-1526	Atopic Dermatitis	Sub-I	3	19-Jul-18
Regeneron	R668-AD-1607	Atopic Dermatitis	Sub-I	1b	10-Apr-18
Roche	CS45570	Atopic Dermatitis	Sub-I	2	ONGOING
Roche	CS45943	Atopic Dermatitis	Sub-I	2	N/A
Sanofi	EFC17561	Atopic Dermatitis	Sub-I	3	03-Feb-26
Sanofi	EFC17599	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	EFC17600	Atopic Dermatitis	Sub-I	3	ONGOING
Sanofi	LPS15496	Atopic Dermatitis	Sub-I	OBS	27-Apr-21
Sanofi	LTS17367	Atopic Dermatitis	Sub-I	2/3	ONGOING
Sanofi	OBS15333	Atopic Dermatitis	Sub-I	OBS	27-Apr-21
Sun Pharmaceuticals	71542612	Atopic Dermatitis	Sub-I	3	15-Feb-18
Taro	RXLC-2118	Atopic Dermatitis	Sub-I	4	04-Dec-24
TrialSpark	ASN008-201	Atopic Dermatitis	Sub-I	2	14-Feb-24
Brickell	BBI-4000-CL-301	Axillary Hyperhidrosis	PI	3	11-Aug-21
CoPharma	PEN-203	Basal Cell Carcinoma	PI	1/2	01-Dec-00
Genentech	THA3435g	Basal Cell Carcinoma	Sub-I	1	27-Jul-06
Akari	AK802	Bullous Pemphigoid	Sub-I	3	08-Sep-22
AstraZenaca	D325AC00002	Bullous Pemphigoid	Sub-I	3	31-Aug-23
Arcutis	ARQ-252-205	Chronic Hand Eczema	PI	1/2b	07-Aug-20
Asana	ASN002AD-202	Chronic Hand Eczema	PI	2	22-Jun-20
Celldex	CDX0159-07	Chronic Inducible Urticaria	PI	2	25-Nov-25
Evomune	EV0756-CIU001	Chronic Inducible Urticaria	PI	2a	20-Jun-25

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Menlo	MTI-117	Chronic Pruritus of Unknown Origin	PI	2	29-May-20
Novartis	CLOU064R12301	Chronic Pruritus of Unknown Origin	PI	3	ONGOING
Sanofi	EFC16973	Chronic Pruritus of Unknown Origin	PI	3	13-Nov-24
Galderma	SPR207913	Chronic Pruritus of Unknown Origin	Sub-I	2	ONGOING
Blueprint Medicines	BLU-808-1201	Chronic Spontaneous Urticaria	PI	2	ONGOING
Celldex	CDX0159-02	Chronic Spontaneous Urticaria	PI	1	10-Jan-23
Celldex	CDX0159-06	Chronic Spontaneous Urticaria	PI	2	07-Nov-23
Celldex	CDX0159-12	Chronic Spontaneous Urticaria	PI	3	ONGOING
Celldex	CDX0159-17	Chronic Spontaneous Urticaria	PI	3b	ONGOING
Esclent	EP-262-201	Chronic Spontaneous Urticaria	PI	2	26-Mar-25
Genentech	ACD4577g	Chronic Spontaneous Urticaria	PI	2	10-Dec-09
Genentech	ML29510	Chronic Spontaneous Urticaria	PI	4	27-Jun-17
Genentech	Q4882g	Chronic Spontaneous Urticaria	PI	3	12-Sep-12
Novartis	CQGE031C2302	Chronic Spontaneous Urticaria	PI	3	30-Sep-22
Novartis	CQGE031C2302E1	Chronic Spontaneous Urticaria	PI	3b	25-Oct-22
Novartis	CQGE031C2201	Chronic Spontaneous Urticaria	PI	2b	29-Jun-16
Amgen	20190194	Chronic Spontaneous Urticaria	Sub-I	2b	20-Apr-23
Evidera	EVA-32391-01	Chronic Spontaneous Urticaria	Sub-I	OBS	13-Mar-23
InflaRX	INF904-P2.1	Chronic Spontaneous Urticaria	Sub-I	2a	04-Dec-25
Jasper Therapeutics	JSP-CP-011	Chronic Spontaneous Urticaria	Sub-I	2a	ONGOING
Jasper Therapeutics	JSP-CP-014	Chronic Spontaneous Urticaria	Sub-I	2	ONGOING
Novartis	CLOU064AUS04	Chronic Spontaneous Urticaria	Sub-I	OBS	ONGOING
Forest	LAS-MD-38	COPD	PI	3b	23-Nov-10
GSK	GTT116855	COPD	PI	3	16-Jun-15
Novartis	CQAB149B2335S	COPD	PI	3	16-Jan-09
Novartis	CQAB149B2341	COPD	PI	3	16-Dec-10
Novartis	CQAB149B2346	COPD	PI	3	16-Dec-08
Novartis	CQVA149A2336	COPD	PI	3	07-May-14
GSK	HZA106837	COPD	Sub-I	3a	22-Nov-11
GSK	LPL100601	Coronary Heart Disease	PI	3	13-Aug-13
Biogen	230LE201	Cutaneous Lupus Erythematosus	Sub-I	2	22-Jul-20
Biogen	230LE301	Cutaneous Lupus Erythematosus	Sub-I	3	31-Oct-23
Biogen	230LE305	Cutaneous Lupus Erythematosus	Sub-I	3	31-Oct-23
Celgene	CC-11050-CLE-002	Cutaneous Lupus Erythematosus	Sub-I	2	01-Dec-12
Gilead	GS-US-497-5888	Cutaneous Lupus Erythematosus	Sub-I	1b	29-Nov-22
Gilead	GS-US-497-6486	Cutaneous Lupus Erythematosus	Sub-I	2a	19-May-26
Janssen	NOCOMPOUNDLUN0001	Cutaneous Lupus Erythematosus	Sub-I	OBS	29-Oct-14
Merck	MS200569-0003	Cutaneous Lupus Erythematosus	Sub-I	2	16-Jan-25
Merck	MS200569-0048	Cutaneous Lupus Erythematosus	Sub-I	1	28-Jan-26
Merck	MS504908_0008	Cutaneous Lupus Erythematosus	Sub-I	3	ONGOING
Pfizer	A6261008	Cutaneous Lupus Erythematosus	Sub-I	3	26-Feb-14
Ventus	VENT-03-201	Cutaneous Lupus Erythematosus	Sub-I	2a	ONGOING
Horizon	HZNP-DAX-202	Cutaneous Lupus Erythematosus	Sub-I	2	21-Nov-25
Nflection	NFX-179-NFI-202	Cutaneous Neurofibroma	PI	2	16-Oct-23

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Regeneron	R2810-ONC-2251	Cutaneous Squamous Cell Carcinoma	PI	3	28-May-26
CastleBio Science	CBI_2019_cSCC_PVS_001	Cutaneous Squamous Cell Carcinoma	Sub-I	4	ONGOING
Elorac	EL-1007-01-01	Cutaneous T-Cell Lymphoma	PI	3	20-Oct-22
Soligenix	HPN-CTCL-01	Cutaneous T-Cell Lymphoma	PI	3	24-Feb-21
Soligenix	HPN-CTCL-03-EUR	Cutaneous T-Cell Lymphoma	PI	3	ONGOING
Lilly	F3Z-US-IOOV	Diabetes - Type 2	PI	3	01-Oct-08
Merck	079-00	Diabetes - Type 2	PI	3	01-Oct-08
Takeda	TAK-875-306	Diabetes - Type 2	PI	3	26-Feb-14
Lilly	H6D-MC-LVGO	Erectile Dysfunciton	PI	3	21-Mar-06
Lilly	I4K-MC-GPEC	Erectile Dysfunciton	Sub-I	2	25-Jan-12
Celgene	CC-10004-PSOR-025	Genital Psoriasis	Sub-I	3	27-Apr-22
Evidera	EVA-16679	Genital Psoriasis	Sub-I	OBS	01-Jun-15
Lilly	I1F-MC-RHBQ	Genital Psoriasis	Sub-I	3	17-May-18
AnaptysBio	ANB019-002	GPP	Sub-I	2a	20-Oct-20
AnaptysBio	ANB019-401	GPP/PPP	Sub-I	3	02-Mar-23
Regeneron	R668-AD-1924	Hand/Foot Dermatitis	PI	3	22-Feb-23
Lilly	J2T-MC-KGCD	Hand/Foot Dermatitis	Sub-I	3b	ONGOING
Lilly	I4J-MC-HHBA	Healthy Volunteers - Biomarkers	Sub-I	N/A	01-Jun-10
Pfarming	C1 1205-01	Hereditary Angioedema	Sub-I	2	07-May-10
Inhibitex	INH-FV1-005	Herpes Zoster	PI	2	10-Dec-10
Abbvie	H13-147	Hidradenitis Suppurativa	PI	OBS	25-Feb-20
AstraZenaca	D5440C00001	Hidradenitis Suppurativa	PI	2a	10-Dec-14
ChemoCentryx	CL016-168	Hidradenitis Suppurativa	PI	2	11-May-21
CSL Bering	CSI324-2001	Hidradenitis Suppurativa	PI	2	10-May-14
Incyte	INCB054707-801	Hidradenitis Suppurativa	PI	3b	ONGOING
Incyte	INCB54707-301	Hidradenitis Suppurativa	PI	3	17-Feb-26
Incyte	INCB54707-302	Hidradenitis Suppurativa	PI	3	23-Jan-26
Incyte	INCB54707-312	Hidradenitis Suppurativa	PI	3	ONGOING
Incyte	INCB54707-312	Hidradenitis Suppurativa	PI	3	ONGOING
Janssen	77474462HDS2001	Hidradenitis Suppurativa	PI	2	10-Feb-23
Moonlake	M1095-HS-201	Hidradenitis Suppurativa	PI	2	02-Oct-23
Moonlake	M1095-HS-301	Hidradenitis Suppurativa	PI	3	ONGOING
Moonlake	M1095-HS-303	Hidradenitis Suppurativa	PI	3	ONGOING
Moonlake	M1095-HS-304	Hidradenitis Suppurativa	PI	3	21-May-26
Novartis	CAIN457M2301E1	Hidradenitis Suppurativa	PI	3	26-Aug-25
Novartis	CAIN457M2302	Hidradenitis Suppurativa	PI	2/3	31-Oct-22
Novartis	CCFZ533H12201BC	Hidradenitis Suppurativa	PI	2	ONGOING
Novartis	CCIM112X2202	Hidradenitis Suppurativa	PI	2	29-Mar-17
Novartis	CLOU064J12301	Hidradenitis Suppurativa	PI	3	ONGOING
Xbiotech	2019-PT047	Hidradenitis Suppurativa	PI	2	21-Feb-21
Abbvie	M20-040	Hidradenitis Suppurativa	Sub-I	2	15-Mar-22
Abbvie	M20-262	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Abbvie	M20-465	Hidradenitis Suppurativa	Sub-I	3	ONGOING
Abbvie	M23-698	Hidradenitis Suppurativa	Sub-I	3	ONGOING

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Acelyrin	21102	Hidradenitis Suppurativa	Sub-I	2	16-Apr-24
Acelyrin	22107	Hidradenitis Suppurativa	Sub-I	3	26-Feb-25
Adelphi	AB6762B	Hidradenitis Suppurativa	Sub-I	OBS	01-Mar-25
Boehringer Ingelheim	1368-0052	Hidradenitis Suppurativa	Sub-I	2a	29-Mar-22
Boehringer Ingelheim	1368-0067	Hidradenitis Suppurativa	Sub-I	2	31-Jan-23
Boehringer Ingelheim	1368-0098	Hidradenitis Suppurativa	Sub-I	2b/3	31-Jul-25
Lilly	I7P-MC-DSAF	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Merck	MK7240-012	Hidradenitis Suppurativa	Sub-I	2b	ONGOING
Pfizer	B7981119	Hidradenitis Suppurativa	Sub-I	2	ONGOING
Pfizer	C2501007	Hidradenitis Suppurativa	Sub-I	2a	15-Feb-22
Sanofi	ACT17841	Hidradenitis Suppurativa	Sub-I	2	19-Feb-26
Novartis	SPP100A-2409	Hypertension	PI	2	21-Jun-10
Mayne	18-ICH-001	Lamellar Ichthyosis	PI	2	17-Jan-22
Timber	TMB01-301/MUST	Lamellar Ichthyosis	PI	3	03-Dec-24
Priovant	PVT-2201-304	Lichen Planopilaris	PI	2/3	ONGOING
Novartis	CGIA362C12201	Lichen Planus	PI	2	ONGOING
Incyte	INCB18424-216	Lichen Planus	Sub-I	2	25-Apr-24
Lilly	I5V-MC-TSAT	Low Testosterone	Sub-I	3	25-Jun-15
Evidera	146323-01	Lower Abdominal Fat	PI	OBS	01-Nov-25
Evidera	152364-01	Lower Abdominal Fat	PI	OBS	01-Jun-26
Evidera	EVA-36509-01	Lower Abdominal Fat	PI	OBS	08-Nov-23
Evidera	EVA-36509-02	Lower Abdominal Fat	PI	OBS	18-Jul-24
Evidera	EVA-36509-04	Lower Abdominal Fat	PI	OBS	23-Jan-25
Evidera	EVA-36509-08	Lower Abdominal Fat	PI	OBS	18-Sep-25
Novan	NI-MC201	Molluscum Contagiosum	Sub-I	2	09-Jan-19
Novan	NI-MC301	Molluscum Contagiosum	Sub-I	3	09-Jan-19
DermTech	17-06	Multi-Indication	PI	4	17-Jun-24
Novartis	CFTY720DUS01	Multiple Sclerosis	PI	4	25-Jul-12
Lilly	I1F-MC-B018	Nail Psoriasis	PI	OBS	29-Jan-25
BioCryst	BCX17725-101	Netherton Syndrome	PI	1	ONGOING
Quoin	CL-QRX003-001	Netherton Syndrome	PI	2	08-Apr-26
Quoin	CL-QRX003-002	Netherton Syndrome	PI	2	ONGOING
Quoin	CL-QRX003-004	Netherton Syndrome	PI	3	ONGOING
Quoin	CL-QRX003-005	Netherton Syndrome	PI	3	ONGOING
Quoin	CL-QRX003-006	Netherton Syndrome	PI	3	ONGOING
DermTech	21-02	Normal Skin	PI	4	29-Jan-24
Mindera	MND-24-MK-02	Normal Skin	Sub-I	1	30-Sep-25
Clexio	CLE400-NP-201	Notalgia Parasthetica	PI	2	24-Jan-25
Cara	CR845-210601	Notalgia Parasthetica	Sub-I	2	11-Aug-22
Cara	CR845-310601	Notalgia Parasthetica	Sub-I	2-3	02-Jul-24
Evidera	EVA-27657	Notalgia Parasthetica	Sub-I	OBS	18-Mar-21
Evidera	EVA-37056-00	Notalgia Parasthetica	Sub-I	OBS	24-Apr-24
Lilly	I1L-MC-GAEB	Obesity	Sub-I	2	16-Jul-10
Hisamitsu	HTU-520-US01	Onychomycosis	PI	2	01-May-13

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
XOMA	X052160	Osteoarthritis of the Hand	PI	2	10-Apr-14
XOMA	X052161	Osteoarthritis of the Hand	PI	2	01-Jun-15
XOMA	X052162	Osteoarthritis of the Hand	PI	2	10-Apr-14
Pfizer	A3191172	Osteoarthritis/Rheumatoid Arthritis	PI	4	19-Sep-16
Novartis	CAIN457A2312	Palmoplantar Psoriasis	PI	3b	03-Apr-17
Abbvie	M15-994	Palmoplantar Psoriasis	Sub-I	3b	17-Jul-23
BMS	IM011-1112	Palmoplantar Psoriasis	Sub-I	4	02-Jul-25
Aristea	RIST4721-202	Palmoplantar Pustulosis	PI	2	12-May-23
AnaptysBio	ANB019-003	Palmoplantar Pustulosis	Sub-I	2	09-Jun-21
Dr. Reddy's	DFD-29-CD-004	Papulopustular Rosacea	PI	3	24-Jul-23
Galderma	RD.06.SPR.18171	Papulopustular Rosacea	PI	3	11-Sep-13
Azitra	CTAR-403	Papulopustular Rosacea	Sub-I	1b/2a	10-Jun-21
Cutanea	CLS001-CO-PR-001.01	Papulopustular Rosacea	Sub-I	2	17-Apr-14
Evidera	EVA-20259	Pediatric Psoriasis	Sub-I	OBS	01-Oct-18
Galderma	RD.06.SPR.202699	Prurigo Nodularis	PI	3	13-Jun-22
Incyte	INGB18424-110	Prurigo Nodularis	PI	1	09-May-25
InnoCare	ICP-CL-00609	Prurigo Nodularis	PI	2	ONGOING
Sanofi	QBS17721	Prurigo Nodularis	PI	4	ONGOING
Galderma	RD.06.SPR.203065	Prurigo Nodularis	Sub-I	3	13-Jun-22
Galderma	SPR207807	Prurigo Nodularis	Sub-I	OBS	ONGOING
Sanofi	EFC16459	Prurigo Nodularis	Sub-I	3	25-May-22
Abbott	P10-023	Psoriasis	PI	OBS	28-Mar-23
Abcentra	ORT-2020-01	Psoriasis	PI	2	21-Feb-23
AbGenomics	2012.005.01	Psoriasis	PI	2a	15-Apr-14
AbGenomics	2014.002.01	Psoriasis	PI	2	09-Apr-15
Alumis	ESK-001-016	Psoriasis	PI	3	17-Feb-26
Alumis	ESK-001-018	Psoriasis	PI	3	ONGOING
Amgen	20030190	Psoriasis	PI	4	04-May-05
Amgen	20040210	Psoriasis	PI	OBS	19-Feb-13
Amgen	20120363	Psoriasis	PI	OBS	12-Apr-17
Arcutis	ARQ-151-302	Psoriasis	PI	3	31-Mar-21
Arcutis	ARQ-151-306	Psoriasis	PI	3	28-Apr-21
Arcutis	ARQ-151-311	Psoriasis	PI	3	08-Nov-22
Arcutis	ARQ-154-204	Psoriasis	PI	2b	02-Dec-20
Aurigene	AUR101-202	Psoriasis	PI	2	12-Oct-22
BMS	IM011-011	Psoriasis	PI	2	23-Aug-17
BMS	IM011-047	Psoriasis	PI	3	19-Jan-21
BMS	IM011-075	Psoriasis	PI	3b	06-May-25
Boehringer Ingelheim	1297.9	Psoriasis	PI	3	01-Jan-19
Centocor	C0168T45	Psoriasis	PI	OBS	20-Jun-06
Dermavant	DMVT-505-3004	Psoriasis	PI	3	11-Mar-26
Dermavant	DMVT-505-3003	Psoriasis	PI	2/3	08-Jun-21
Genentech	ACD3101g	Psoriasis	PI	3b	07-Oct-09
GSK	200853	Psoriasis	PI	3	01-May-21
InventisBio	D2570-207	Psoriasis	PI	2	ONGOING

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Janssen	CNT01275PSO3013	Psoriasis	PI	3	05-Oct-17
Janssen	CNT01959PSO3009	Psoriasis	PI	3	30-Oct-18
Nimbus	4858-201	Psoriasis	PI	2b	05-Dec-22
Novartis	CAIN457A2310	Psoriasis	PI	3	31-Oct-18
Novartis	CAIN457A2313	Psoriasis	PI	3b	04-Apr-17
Novartis	CAIN457A2326	Psoriasis	PI	3	26-Sep-18
Novartis	CAIN457AUS07	Psoriasis	PI	4	03-Jun-19
Novartis	CCJM112X2101	Psoriasis	PI	1	26-Jan-16
Pfizer	A3921061	Psoriasis	PI	3	11-Oct-16
Pfizer	A3921078	Psoriasis	PI	3	06-Jan-14
Promius	DFD06-CD-005	Psoriasis	PI	3	29-Aug-16
Schering Plough	PO5495	Psoriasis	PI	2	30-Jan-13
Sienna	SNA-120-202	Psoriasis	PI	2	01-Feb-19
Stiefel	STF115750	Psoriasis	PI	1	30-Aug-17
Takeda	TAK279-3001	Psoriasis	PI	3	20-Jan-26
Takeda	TAK279-3003	Psoriasis	PI	3	ONGOING
Takeda	TAK-279-PsO-3004	Psoriasis	PI	3	02-Jun-26
Abbott	M03-656	Psoriasis	Sub-I	3	18-Sep-06
Abbott	M03-658	Psoriasis	Sub-I	3	15-Oct-09
Abbott	M05-736	Psoriasis	Sub-I	2	07-Jul-08
Abbott	M06-890	Psoriasis	Sub-I	3	29-Jul-09
Abbott	M10-016	Psoriasis	Sub-I	3	06-Mar-12
Abbott	M10-114	Psoriasis	Sub-I	3	15-Apr-09
Abbott	M10-238	Psoriasis	Sub-I	3	09-Jul-09
Abbott	P10-023	Psoriasis	Sub-I	OBS	28-Mar-23
Abbvie	M15-997	Psoriasis	Sub-I	3	20-Mar-23
Abbvie	M18-816	Psoriasis	Sub-I	2	20-Mar-23
Abbvie	M19-164	Psoriasis	Sub-I	3b	29-Sep-22
Abbvie	M19-164 Companion	Psoriasis	Sub-I	3b	29-Sep-22
Abbvie	M20-326	Psoriasis	Sub-I	4	17-Jul-23
Abbvie	M24-541	Psoriasis	Sub-I	4	02-Jun-26
Akros	AE451-G-18-004	Psoriasis	Sub-I	2/3	12-May-20
Allergan	1957-201-001	Psoriasis	Sub-I	2b	22-May-18
Amgen	20030190	Psoriasis	Sub-I	4	04-May-05
Amgen	20040210	Psoriasis	Sub-I	OBS	19-Feb-13
Amgen	20070559	Psoriasis	Sub-I	3	15-Mar-11
Amgen	20101177	Psoriasis	Sub-I	4	18-Mar-16
Amgen	20120104	Psoriasis	Sub-I	3	22-Dec-15
Amgen	20190232	Psoriasis	Sub-I	3	08-Sep-22
Amgen	20200196	Psoriasis	Sub-I	3	ONGOING
Amgen	HRA1603A (20130126)	Psoriasis	Sub-I	OBS	11-Feb-16
Amgen	HRA1889A	Psoriasis	Sub-I	OBS	20-Aug-14
Astellas	04-0-206	Psoriasis	Sub-I	3	05-Apr-07
Baxalta	911401	Psoriasis	Sub-I	3	24-Oct-17

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Biocon	BIO-USTEKI-305	Psoriasis	Sub-I	3	20-Dec-22
Biocon	BM12H-PSO-03-G-02	Psoriasis	Sub-I	3	11-Jan-24
BMS	IM011-1128	Psoriasis	Sub-I	3	ONGOING
BMS	IM011-1130	Psoriasis	Sub-I	3b/4	ONGOING
Boehringer Ingelheim	1311.28	Psoriasis	Sub-I	3	21-Nov-17
Boehringer Ingelheim	1407-0005	Psoriasis	Sub-I	2	21-Oct-21
Boehringer Ingelheim	1407-0030	Psoriasis	Sub-I	2	22-Jul-21
Celgene	CC-10004-PPSO-003	Psoriasis	Sub-I	3	03-Aug-23
Celgene	CC-10004-PPSO-004	Psoriasis	Sub-I	3b	24-Mar-26
Celgene	CC-10004-PSOR-005	Psoriasis	Sub-I	2b	26-Jan-10
Celgene	CC-10004-PSOR-005E	Psoriasis	Sub-I	2b	11-Aug-10
Celgene	CC-10004-PSOR-008	Psoriasis	Sub-I	3	06-Oct-16
Celgene	CC-10004-PSOR-010	Psoriasis	Sub-I	3b	15-Jul-15
Celgene	CC-10004-PSOR-022	Psoriasis	Sub-I	3	22-Oct-20
Centocor	C0379T04	Psoriasis	Sub-I	2	17-Jun-05
Centocor	C0743T08	Psoriasis	Sub-I	3	27-Jul-11
Centocor	C0743T09	Psoriasis	Sub-I	3	16-Dec-11
Centocor	C0743T12	Psoriasis	Sub-I	3	26-Feb-09
CorEvitas	CorEvitas-PSO-505	Psoriasis	Sub-I	OBS	ONGOING
Corrona	Corrona-PSO-550	Psoriasis	Sub-I	4	ONGOING
Dermavant	DMVT-505-3001	Psoriasis	Sub-I	3	22-Jul-20
Dermira	PS0003	Psoriasis	Sub-I	3	13-Mar-19
DICE Therapeutics	DCE806201	Psoriasis	Sub-I	2	28-Mar-24
Dr. Reddy's	PPC-06-CD-004	Psoriasis	Sub-I	2	28-May-19
Evidera	EVA-18225	Psoriasis	Sub-I	OBS	02-Jun-16
Evidera	EVA-18225-01	Psoriasis	Sub-I	OBS	03-Aug-16
Galderma	RD.06.SPR.18104	Psoriasis	Sub-I	4	25-Feb-16
Galderma	RD.06.SPR.18131	Psoriasis	Sub-I	4	29-Aug-18
Genentech	ACD2600g	Psoriasis	Sub-I	3	12-Jun-03
Genentech	ACD2601g	Psoriasis	Sub-I	3	15-Jul-04
Genentech	ACD3101g	Psoriasis	Sub-I	3b	07-Oct-09
Genentech	ACD3753g	Psoriasis	Sub-I	4	04-Jan-07
Genentech	ACD4412n	Psoriasis	Sub-I	4	20-Sep-09
Genzyme	HECTPS02507	Psoriasis	Sub-I	2	13-May-09
GSK	200851	Psoriasis	Sub-I	3	01-Dec-13
Janssen	38515168PSO2001	Psoriasis	Sub-I	2	13-Jan-16
Janssen	CNT01959PSO2001	Psoriasis	Sub-I	2	01-Nov-13
Janssen	CNT01959PSO3002	Psoriasis	Sub-I	3	10-Sep-20
Janssen	CNT01959PSO3003	Psoriasis	Sub-I	3	19-Jul-16
Janssen	77242113PSO2001	Psoriasis	Sub-I	2b	28-Sep-22
Janssen	77242113PSO2002	Psoriasis	Sub-I	2b	23-Jan-23
Janssen	77242113PSO3001	Psoriasis	Sub-I	3	19-Mar-24
Janssen	77242113PSO3002	Psoriasis	Sub-I	3	20-Feb-25
Janssen	77242113PSO3003	Psoriasis	Sub-I	3	14-Jan-25

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Janssen	CNT01959PSO3018	Psoriasis	Sub-I	3b	10-Sep-25
Kadmon	KD025-211	Psoriasis	Sub-I	2	07-Nov-19
Lilly	F1P-MC-KFAC	Psoriasis	Sub-I	1	03-Nov-21
Lilly	I1F-MC-RHAG	Psoriasis	Sub-I	2	02-Jun-10
Lilly	I1F-MC-RHAZ	Psoriasis	Sub-I	3	23-Jan-19
Lilly	I1F-MC-RHBC	Psoriasis	Sub-I	3	17-Dec-19
Lilly	I1F-MC-RHBL	Psoriasis	Sub-I	3	03-Oct-13
Lilly	I1F-MC-RHBP	Psoriasis	Sub-I	3	07-Jun-17
Lilly	I1F-MC-RHCR	Psoriasis	Sub-I	4	23-Jul-20
Lilly	I1F-MC-RHDC	Psoriasis	Sub-I	3b	ONGOING
Lilly	I1F-MC-RHDD	Psoriasis	Sub-I	3b	ONGOING
Lilly	I1X-MC-BDAD	Psoriasis	Sub-I	2	30-Jul-10
Lilly	I6T-MC-AMAH	Psoriasis	Sub-I	3	28-Apr-22
Lilly	I6T-MC-AMAJ	Psoriasis	Sub-I	3	22-Jul-20
Lilly	I6T-MC-AMBK	Psoriasis	Sub-I	2/3	28-Jul-21
Lilly	I7P-MC-DSAB	Psoriasis	Sub-I	1	29-Aug-19
Lilly	I7P-MC-DSAB	Psoriasis	Sub-I	1	29-Aug-19
LITE	PCS-1608-35830	Psoriasis	Sub-I	2/3	05-Jul-24
Maruho	M518101-US01	Psoriasis	Sub-I	2b	07-Mar-12
Maruho	M518101-US02	Psoriasis	Sub-I	3	11-Sep-15
Merck	MK3222-010	Psoriasis	Sub-I	3	28-Jan-20
Mindera	MND-21-MKPs-02	Psoriasis	Sub-I	4	28-May-24
Novartis	CAIN457A2223	Psoriasis	Sub-I	2	08-May-15
Novartis	CAIN457A2302E1	Psoriasis	Sub-I	3	18-Nov-17
Novartis	CAIN457A2303	Psoriasis	Sub-I	3	04-Apr-17
Novartis	CAIN457A2304	Psoriasis	Sub-I	3	25-Oct-17
Novartis	CAIN457A2304E1	Psoriasis	Sub-I	3	25-Oct-17
Novartis	CAIN457A2317	Psoriasis	Sub-I	3b	19-Nov-16
Novartis	CAIN457A2324	Psoriasis	Sub-I	3b	10-Nov-20
Novo-Nordisk	NN8226-1848	Psoriasis	Sub-I	1/2a	03-Mar-11
Pfizer	B7451005	Psoriasis	Sub-I	2	02-Sep-15
Pfizer	B7931004	Psoriasis	Sub-I	2a	08-May-18
Pfizer	B7931004	Psoriasis	Sub-I	2a	08-May-18
PSOLAR	C0168Z03	Psoriasis	Sub-I	OBS	18-May-23
Sandoz	GP17-301	Psoriasis	Sub-I	3	24-Jul-16
Sanofi	DRI17849	Psoriasis	Sub-I	2	03-Dec-24
Sun Pharmaceuticals	71542611	Psoriasis	Sub-I	3	16-Feb-18
Tolmar	TOL2707A	Psoriasis	Sub-I	3	02-Jun-16
UCB	PS0003	Psoriasis	Sub-I	3	01-Apr-18
UCB	PS0010	Psoriasis	Sub-I	2b	12-Jun-17
UCB	PS0020	Psoriasis	Sub-I	2	17-Jul-24
UCB	PS0021	Psoriasis	Sub-I	3	ONGOING
UPENN	CP3	Psoriasis	Sub-I	4	ONGOING
Ventyx	VTX958-201	Psoriasis	Sub-I	2	13-Feb-24

Kenneth W. Dawes, MD

Sponsor	Protocol	Indication	Role	Phase	Date of COV
Wyeth	3199K2-1105-US	Psoriasis	Sub-I	1	06-Dec-10
Wyeth	3226K1-1002-WW	Psoriasis	Sub-I	1	19-Sep-11
Abbvie	H15-457	Psoriatic Arthritis	PI	OBS	25-Oct-17
Janssen	CNT01959PSA3001	Psoriatic Arthritis	PI	3	10-Jul-18
Janssen	CNT01959PSA3002	Psoriatic Arthritis	PI	3	10-Jul-18
Amgen	20030106	Psoriatic Arthritis	Sub-I	3	09-Nov-04
Celgene	CC-10004-PSA-004	Psoriatic Arthritis	Sub-I	3	14-Dec-12
Janssen	CNT01275PSA3001	Psoriatic Arthritis	Sub-I	3	06-Aug-13
Janssen	CNT01275PSA3002	Psoriatic Arthritis	Sub-I	3	17-Jan-13
Janssen	CNT0148PSA3001	Psoriatic Arthritis	Sub-I	3	08-Sep-15
Janssen	CNT01959PSA2001	Psoriatic Arthritis	Sub-I	2a	01-Mar-17
Nimbus	4858-202	Psoriatic Arthritis	Sub-I	2b	29-Mar-23
Novartis	CAIN457A02001B	Psoriatic Arthritis	Sub-I	4	23-Jan-25
Novartis	CAIN457F2318	Psoriatic Arthritis	Sub-I	3	06-Sep-18
Novartis	CAIN457P12302	Psoriatic Arthritis	Sub-I	3	12-Sep-22
Boehringer Ingelheim	1368-0140	Pyoderma Gangrenosum	Sub-I	3	ONGOING
Merck	MK-0663-107	Rheumatoid Arthritis	Sub-I	3	29-Jul-14
Galderma	GLI-04-SPR US10120	Rosacea	PI	4	01-Nov-09
Perrigo	PRG-NY-14-022	Rosacea	PI	3	17-Nov-15
Cutanea	CLS001-CO-PR-006	Rosacea	Sub-I	3	07-Mar-18
BMS	IM011-220	Scalp Psoriasis	Sub-I	3b/4	19-Nov-24
Evidera	EVA-20371-01	Scalp Psoriasis	Sub-I	OBS	11-Jan-24
Arcutis	ARQ-154-304	Seborrheic Dermatitis	PI	3	06-Jul-22
Lilly	F1K-US-EVDO	Sepsis	PI	4	01-Oct-09
Evidera	EVA-44850	Skin Tone Assessment	Sub-I	OBS	ONGOING
Merck	009-00	Vaccine	Sub-I	2	26-Feb-13
RXI	RXI-SCP-1502	Verruca Vulgaris	Sub-I	2a	06-Sep-18
DRG Abacus	8493	Vitiligo	PI	OBS	01-Dec-20
Incyte	INCB18424-211	Vitiligo	PI	2	28-Aug-20
Novartis	CGIA362B12201	Vitiligo	PI	2	ONGOING
Abbvie	M19-044	Vitiligo	Sub-I	3	ONGOING
Abbvie	M19-051	Vitiligo	Sub-I	2	09-Nov-23
Abbvie	M25-264	Vitiligo	Sub-I	3	ONGOING
Evidera	EVA-31203-01	Vitiligo	Sub-I	OBS	31-Oct-22
Lilly	J5D-MC-FPAD	Vitiligo	Sub-I	2	ONGOING
Merck	MK-6194-007	Vitiligo	Sub-I	2a	20-May-25
Pfizer	B7981040	Vitiligo	Sub-I	3	05-Mar-26
Pfizer	B7981041	Vitiligo	Sub-I	3	ONGOING
Pfizer	B7981080	Vitiligo	Sub-I	3	10-Sep-25
VYNE	VY2024-02	Vitiligo	Sub-I	2b	30-Jul-25
Aclaris	A-101-WART-202	Warts	PI	2	11-Apr-18
Aclaris	A-101-WART-301	Warts	PI	3	26-Nov-19
Aclaris	A-101-WART-303	Warts	PI	3	29-Jan-20
Cutanea	CLS006-CO-PR-002	Warts	Sub-I	3	22-Jan-19